drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to deliver costimulatory signals and enhance T-cell activation in PSMA-positive settings.
nci_thesaurus_concept_id
C202466
nci_thesaurus_preferred_term
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401
nci_thesaurus_definition
A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-PSMA/anti-CD28 bispecific antibody JNJ-87189401 binds to both CD28 expressed on cytotoxic T-lymphocytes (CTLs) and PSMA expressed on tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to provide CD28-mediated costimulation, enhancing T-cell activation and redirecting cytotoxicity toward PSMA-positive tumor cells.
drug_name
JNJ-87189401
nct_id_drug_ref
NCT06095089